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Abstract
Background:  Type  1  diabetes  (T1D)  and  celiac  disease  (CD)  are  the  two  most  common  autoim-
mune childhood  diseases  that  share  their  HLA-DQ2  and  DQ8  genetic  origin.  There  has  been
a current  increase  in  both  diseases  worldwide.  In  children  from  the  low-population  State  of
Sonora (15  inhabitants/km2)  in  northwestern  Mexico,  there  is  no  information  on  their  genetic
risk or  the  distribution  of  the  related  alleles  in  the  general  population.
Aims: To  compare  the  HLA-DQ  allele  frequency  in  a  representative  sample  of  newborns  from
Sonora with  that  of  T1D  and  CD  patients  to  determine  the  risk  gradient  and  identify  the  presence
of celiac  autoimmunity  in  the  T1D  group.
Methods:  The  study  included  397  Sonoran  newborns,  44  cases  of  T1D,  and  25  CD  cases.  The  CD
and T1D  cases  were  clinically  diagnosed  by  specialists  at  the  Hospital  Infantil  del  Estado  de
Sonora and  the  autoantibodies  were  determined  by  ELISA.  Whole  blood  was  collected,  gDNA
was extracted,  and  HLA-DQ2  and  DQ8  were  typed  by  PCR-SSP.  The  risk  gradient  was  calculated
by comparing  the  allele  frequencies  of  the  cases  with  those  of  the  newborns.
Results:  The  Sonoran  HLA-DQ  risk  heterodimer  proportion  was  16.1%  for  HLA-DQ2  and  13.6%
for HLA-DQ8  with  an  HLA-DQ2:  HLA-DQ8  ratio  of  1.2:1.  The  DQ8/DQ2  genotype  represented  a
1:14 risk  for  T1D,  whereas  the  DQ8/DQB1*0201  combination  resulted  in  a  1:6  risk  for  CD.  The
prevalence  of  CD  autoimmunity  in  T1D  children  was  7%. Please cite this article as: Mejía-León ME, Ruiz-Dyck KM, Calderón de la Barca AM. Gradiente de riesgo genético HLA-DQ para diabetes
tipo 1 y enfermedad celíaca en el noroeste de México. Revista de Gastroenterología de México. 2015;80:135--143.
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Conclusion:  The  Sonoran  population  has  a  distinctive  HLA-DQ  allele  distribution  due  to  its  ances-
try. The  HLA-DQ8  combinations  with  DQ2  or  one  of  its  alleles  conferred  the  highest  risk  for  both
diseases  and  T1D  and  CD  frequently  appear  together.
© 2015  Asociación  Mexicana  de  Gastroenterología.  Published  by  Masson  Doyma  México  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Gradiente  de  riesgo  genético  HLA-DQ  para  diabetes  tipo  1  y  enfermedad  celíaca  en  el
noroeste  de  México
Resumen
Antecedentes:  La  diabetes  tipo  1  (DT1)  y  la  enfermedad  celíaca  (EC)  son  2  enfermedades
autoinmunes  frecuentes  en  la  infancia  y  comparten  su  predisposición  genética  (HLA-DQ2  y
DQ8). La  prevalencia  de  ambas  se  ha  incrementado  en  el  mundo.  En  el  estado  de  Sonora  (15
habitantes/km2),  se  desconoce  información  sobre  su  riesgo  genético  o  la  distribución  de  los
alelos asociados  en  la  población  general.
Objetivo:  Comparar  la  frecuencia  alélica  HLA-DQ  de  una  muestra  representativa  de  recién
nacidos sonorenses  con  la  de  pacientes  DT1  y  EC  para  determinar  el  gradiente  de  riesgo  e
identiﬁcar  la  presencia  de  autoinmunidad  celíaca  en  el  grupo  de  DT1.
Métodos:  Se  incluyeron  397  recién  nacidos  sonorenses,  44  casos  DT1  y  25  EC,  diagnosticados
clínicamente  y  con  autoanticuerpos  por  ELISA.  Se  colectó  una  muestra  de  sangre,  se  extrajo
ADNg y  tipiﬁcaron  HLA-DQ2  y  DQ8  por  PCR.  El  gradiente  de  riesgo  se  calculó  comparando  las
frecuencias  alélicas  de  los  casos  con  respecto  a  los  recién  nacidos.
Resultados:  La  proporción  de  heterodímeros  de  riesgo  en  sonorenses  fue  de  16.1%  para  HLA-
DQ2 y  de  13.6%  para  HLA-DQ8  con  una  proporción  HLA-DQ2:DQ8  de  1.2:1.  El  genotipo  DQ8/DQ2
representó  un  riesgo  de  1:14  para  DT1,  mientras  que  para  EC  el  DQ8/DQB1*0201  generó  un
riesgo de  1:6.  La  prevalencia  de  autoinmunidad  asociada  a  EC  fue  del  7%  en  los  nin˜os  DT1.
Conclusión:  Los  sonorenses  tienen  una  distribución  de  alelos  HLA-DQ  distintiva  debido  a  su
ascendencia.  Las  combinaciones  del  HLA-DQ8  con  DQ2  o  uno  de  sus  alelos  conﬁrieron  el  máximo
riesgo para  ambas  enfermedades.  La  DT1  y  EC  frecuentemente  se  presentan  juntas.
© 2015  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.  Este
es un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/
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ntroduction
ype  1  diabetes  (T1D)  is  a  chronic  disease  caused  by
utoimmune-mediated  destruction  of  pancreatic  beta  cells,
sually  leading  to  absolute  insulin  deﬁciency1. Celiac
isease  (CD)  is  another  inﬂammatory  systemic  disease,
rimarily  affecting  the  small  intestine,  caused  by  an
mmune-based  reaction  to  dietary  gluten  (storage  protein
or  wheat,  barley,  and  rye)  in  individuals  with  a  genetic  pre-
isposition  and  it  is  resolved  by  excluding  gluten  from  the
iet2.
T1D  and  CD  are  the  2  most  common  autoimmune  child-
ood  diseases,  with  a  prevalence  of  1:100  to  1:200  for  CD3
nd  1:300  for  T1D4.  In  addition,  the  prevalence  of  CD  in  T1D
atients  appears  to  be  20  times  higher5,  being  frequently
nder-diagnosed  because  adherence  to  diagnostic  guidelines
n  current  practice  varies  widely6.  These  immune-mediated
iseases  share  some  characteristics  involving  environment
nd  genetics7.
The  class  II  human  leukocyte  antigen  (HLA)  is  the  sin-
le  most  important  genetic  factor  for  autoimmune  diseases
uch  as  T1D  and  CD,  mainly  the  DQ  and  DR  isotypes8.
hus,  the  HLA  DQ2  and  DQ8  haplotypes  contribute  to  over
0%  of  the  genetic  load  for  both  disorders9,10.  Expressed
T
o
pLA-DQ  molecules  are  heterodimers  of    and    polymorphic
hains  that  can  be  encoded  in  cis  or  trans11. In  antigen-
resenting  cells  of  the  immune  system,  these  molecules
peciﬁcally  bind  peptides,  such  as  those  derived  from  gluten
hat  induce  CD,  as  well  as  peptides  from  islet  autoantigens,
ncluding  insulin,  that  degenerate  in  T1D12.
In  Europe,  around  90-95%  of  celiac  patients  have  the  HLA-
Q2  haplotype,  composed  of  the  DQA1*0501/DQB1*0201
lleles,  while  the  other  5-10%  have  the  HLA-DQ8  haplo-
ype  with  DQA1*0301/DQB1*030213.  These  same  haplotypes
re  present  in  about  90%  of  T1D  patients14. However,  a
igher  risk  has  been  associated  with  HLA-DQ8,  in  con-
rast  to  CD,  in  which  HLA-DQ2  provides  the  greatest  risk15.
lthough  other  factors  have  been  studied  for  these  dis-
ases,  such  as  affected  relatives,  dietary  pattern,  and
arly  intestinal  infections,  the  HLA  risk  genotype  is  the
nly  known  factor  that  is  signiﬁcantly  associated  with
he  development  of  CD  autoimmunity16.  Therefore,  the
ossibility  of  stratifying  the  individuals  based  on  their
LA-DQ  status  is  necessary  to  implement  preventive  and
herapeutic  targeted  interventions  for  these  diseases17,18.
his  approach  would  favor  personalized  health  care  devel-
pment,  adapted  to  the  local  characteristics  of  each
opulation.
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pHLA-DQ  genetic  risk  gradient  for  type  1  diabetes  and  celiac  
In  northwestern  Mexico,  the  State  of  Sonora  presents
unique  characteristics  with  respect  to  its  territory  and
inhabitants.  Sonora  is  the  second  largest  state  in  Mex-
ico,  with  an  area  of  179,516  km2 and  a  population  of
2,662,480  people19,  corresponding  to  a  population  density
of  less  than  15  inhabitants/km2.  In  addition,  due  to  the
fact  that  most  of  the  Sonoran  territory  is  desert,  inhabitants
have  remained  relatively  isolated  from  the  rest  of  the  coun-
try.  Thus,  the  Sonoran  admixture  population  has  the  highest
European  and  the  lowest  Amerindian  ancestry  contribution
compared  with  other  Mexican  populations20.  However,  no
data  on  the  frequency  of  the  HLA-DQ2  and  DQ8  alleles  in
the  general  population  are  known  to  date.
There  has  been  a  current  increase  in  cases  of  T1D  and
CD  in  Sonoran  children  whose  population  is  a  special  admix-
ture  group.  Therefore,  the  aim  of  this  study  was  to  compare
the  HLA-DQ  allele  frequency  in  newborns  from  Sonora  with
patients  that  have  T1D  and  CD  to  determine  their  risk  gradi-
ent  and  to  identify  the  presence  of  celiac  autoimmunity  in
the  T1D  group.
Methods
Subjects
An  analytical  cross-sectional  study  was  conducted  in  Sonora,
Mexico,  with  children  seen  at  the  Hospital  Infantil  del
Estado  de  Sonora.  It  is  the  largest  regional  children’s  hos-
pital  and  at  least  90%  of  the  parents  and  grandparents  of
the  patients  were  born  in  the  Mexican  Northwest 21.
The  appropriate  sample  size  for  the  reference  group  was
determined  by  the  formula  for  proportions,  n  =  (Z2pq)/d2,
taking  into  account  the  total  Sonoran  population
(2,662,384  people),  an  estimated  30%  prevalence  of
HLA  DQ2  and  DQ8  haplotypes  in  other  populations,  and
a  conﬁdence  level  of  95%  with  a  margin  of  error  of  5%.
Similarly,  for  the  T1D  and  CD  case  groups,  the  expected
prevalence  of  1:300  and  1:200  was  considered,  as  well  as
the  fact  that  more  than  90%  of  the  patients  with  these
diseases  have  the  DQ  haplotypes.  In  accordance  with  this
approach,  323  controls,  16  CD  cases,  and  8  T1D  cases  were
required.
Based  on  the  above,  the  control  sample  consisted  of  397
infants,  born  at  the  end  of  2010  and  the  beginning  of  2011
and  accounting  for  14.5%  of  the  newborn  babies  at  the  Hos-
pital  Infantil  del  Estado  de  Sonora  during  the  collecting
period.  For  the  case  groups,  a  total  of  44  children  and  ado-
lescents  with  T1D  and  25  with  CD,  ranging  from  2  to  18  years
of  age,  were  recruited  during  the  years  of  2012-2014.  The
patient  sample  represents  the  totality  of  T1D  and  CD  cases
detected  in  that  hospital  during  the  sampling  period.  CD
diagnoses  were  conﬁrmed  by  the  Marsh  score  determined
through  small  bowel  biopsy  and  anti-tissue  transglutaminase
(tTG)/anti-gliadin  serum  antibodies.  Likewise,  T1D  diag-
noses  were  established  according  to  the  American  Diabetes
Association  criteria1,  including  positive  anti-GAD  and/or
anti-IA-2  antibodies.Ethical  approval
All  procedures  performed  were  approved  by  the  Ethics  Com-
mittee  of  the  Center  for  Food  Research  and  Development
s
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CIAD)  and  by  the  Hospital  Infantil  del  Estado  de  Sonora
earning  and  Research  Board,  in  accordance  with  the  stan-
ards  of  the  1964  Helsinki  Declaration  and  its  Good  Clinical
ractice  guidelines.  Informed  consent  was  obtained  from
he  legal  guardians  of  all  individual  participants  included
n  the  study.
ample  collection
mbilical  cord  blood  was  collected  at  the  time  of  delivery
n  all  the  controls  and  stored  at  4 ◦C  for  HLA  typing.  Further-
ore,  5  mL  of  peripheral  blood  of  all  T1D  and  CD  cases  were
ollected,  from  which  2  mL  were  taken  for  DNA  extraction.
he  serum  from  the  remaining  sample  was  then  separated
nd  reserved  for  serologic  screening.
NA  extraction  and  HLA  typing
enomic  DNA  was  extracted  from  whole  blood  samples
sing  the  QIAamp  DNA  Mini  Kit  (Qiagen®, Hilden,  Ger-
any),  according  to  the  manufacturer’s  instructions.  HLA
Q2  and  DQ8  typing  was  performed  using  the  polymerase
hain  reaction  with  sequence  speciﬁc  primers  (PCR-SSP)
or  the  DQA1*0501,  DQA1*0301,  DQB1*0201,  and  DQB1*0302
lleles  (IDT-Integrated  DNA  Technologies,  Tucson,  AZ,  USA),
s  reported  by  Olerup  et  al.22 The  ampliﬁed  PCR  products
btained  were  analyzed  on  1.8%  agarose  gels,  stained  with
elRedTM (Biotium  Inc.,  Hayward,  CA,  USA),  and  visualized
nder  ultraviolet  light  (Molecular  Imager®Bio-Rad,  Hercules,
A,  USA).  The  HLA  DQ2  and  DQ8  haplotypes  were  conﬁrmed
ssessing  the  DRB1*03  and  DRB1*04  associated  alleles  from
he  HLA-DR  fraction  through  PCR-SSP.
The  HLA  allele  frequencies  in  our  sample  were  calculated
y  the  direct  counting  method  and  compared  through  a  Chi-
quared  test  using  NCSS  analysis  software  version  2007.  A  p
alue  <  0.05  was  considered  statistically  signiﬁcant.
isk  gradient
fter  the  4  HLA-DQ  risk  allele  assessment,  16  possible  posi-
ivity  patterns  were  expected,  thus  obtaining  the  different
ombinations  in  which  the  HLA-DQ  risk  alleles  were  present
n  both  the  T1D  and  CD  cases.  These  combinations  were
sed  for  the  analysis.  For  nomenclature  purposes,  the  term
Q2  was  used  only  when  a  subject  carried  the  DQA1*0501
llele  and  the  DQB1*0201  allele.  Likewise,  DQ8  referred  only
o  subjects  with  both  the  DQA1*0301  and  the  DQB1*0302
llele.  The  subjects’  phenotypes  encoded  by  only  one  of
hese  alleles,  forming  dimers  with  a  different  chain,  were
amed  A1*0501,  B1*0201,  A1*0301,  or  B1*0302,  respectively.
T1D  and  CD  risks  were  expressed  as  1:N,  where  N  is  the
umber  of  individuals  among  whom  one  patient  is  present,  as
reviously  described  by  Megiorni  et  al.23 Thereby,  N  was  cal-
ulated  as  the  percentage  of  the  controls  (Sonoran  newborns
rom  the  general  population)  with  that  particular  HLA-DQ
tatus  multiplied  by  100  and  divided  by  the  percentage  of
atients  with  the  same  DQ  typing.  For  this  analysis,  we  con-
idered  the  reported  prevalence  of  1:300  for  T1D  and  1:100
o  1:200  for  CD,  placing  the  results  into  perspective.  To  con-
rm  the  strength  of  the  estimated  gradient,  odds  ratios  (OR)
ere  calculated  for  each  combination  of  alleles.
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Table  1  Allele  frequencies  of  the  HLA-DQ2  and  HLA-DQ8  haplotypes  in  Sonoran  newborns  compared  with  different  Mestizo  and
European ethnic  groups.
Mexican
Mestizo
Latin  American
Mestizo
Basque  Spanish  Slovenian
Alleles  Sonoran  newborns
n  =  397
Frequency
Frequency
range
Frequency  range  n  =  83
Frequency
n  =  301
Frequency
n  =  70
Frequency
DQA1*0501 0.233a 0.222-0.227a 0.091-0.169b 0.260a 0.223a 0.429c
DQB1*0201  0.132a 0.163-0.167a 0.125a 0.480b 0.462b 0.329b
DQA1*0301  0.232a 0.257-0.296a 0.258-0.295a 0.127b 0.166b 0.129b
DQB1*0302  0.105a 0.237-0.278b 0.242-0.295b 0.067a 0.193b 0.143a
n: sample size.
The different superscripts indicate signiﬁcant differences (p < 0.05) between Sonoran newborns and each population.
Mexican Mestizo: (n = 54)25, (n = 198)26, (n = 99)27.
Latin American Mestizo: (n = 124)28, (n = 51)29.
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Slovenian15.
erologic  Screening
he  T1D  diagnoses  were  complemented  by  anti-GAD  and
nti-IA-2  antibody  quantiﬁcation  with  a  commercial  ELISA
it  according  to  the  company’s  instructions  (Kronus®, USA).
nti-transglutaminase  IgA  and  anti-gliadin  IgG  and  IgA  titers
rom  serum  were  also  measured  by  ELISA,  using  enzymat-
cally  digested  gliadins  extracted  in  our  laboratory.  ELISA
as  run  as  previously  performed  in  our  lab24,  including  the
eﬁnition  for  the  cutoff  values.
esults
he  risk  heterodimer  frequency  proportion  for  newborns
rom  Sonora  in  northwestern  Mexico  was  16.1%  for  HLA-DQ2
nd  13.6%  for  HLA-DQ8,  with  a  HLA-DQ2:HLA-DQ8  ratio  of
.2:1.  The  HLA-DQ2.5  and  HLA-DQ8  allele  frequencies  in
ewborns  are  presented  in  Table  1.  The  third  and  fourth
olumns  show  the  range  of  allele  frequencies  from  other
opulations,  such  as  Mexican  Mestizos25--27 and  Latin  Ameri-
an  Mestizos28,29.  As  expected,  Sonoran  children  alleles  were
loser  to  those  of  Mexican  Mestizos  than  those  of  other
atin  American  Mestizos.  Only  one  of  the  4  alleles  that  were
ompared  (DQB1*0302)  had  a  lower  frequency  for  Sonoran
hildren  than  for  Mexican  Mestizos.  Additionally,  there  was
 higher  frequency  for  DQA1*0501  (p  <  0.05)  in  Sonoran  chil-
ren  than  in  Latin  American  Mestizos.  The  highest  allele
requencies  in  newborns  from  Sonora  were  for  DQA1*0501
0.233)  and  DQA1*0301  (0.232).
In  the  last  columns,  Table  1  shows  the  comparison  of
onoran  newborns  with  general  Spanish  and  Basque  popu-
ations;  a  Slovenian  population  was  used  as  a  Caucasian
eference.  There  were  no  signiﬁcant  differences  (p  >  0.05)
mong  Sonoran  newborns  and  Basques  or  Spaniards  for
QA1*0501  allele  frequency,  as  reported  by  Sánchez-Velasco
t  al.30 and  Planelles  et  al.31 The  low  frequency  of  the
QB1*0302  allele  for  Sonoran  newborns  in  this  study  was  only
omparable  (p  >  0.05)  to  the  allele  frequency  of  Basques30
nd  Slovenians.  There  was  absolutely  no  other  similarity
etween  Sonoran  children  and  Slovenians15 in  relation  to  any
f  the  remaining  3  alleles  analyzed.
a
g
h
CRegarding  the  T1D  and  CD  Sonoran  cases,  we  found  a
imilar  frequency  in  the  alleles  studied,  when  comparing
he  2  groups  (p  > 0.05).  However,  a  comparison  of  these
roups  with  data  from  Sonoran  newborns,  showed  that  T1D
nd  CD  patients  had  an  allele  frequency  of  DQB1*0201  and
QB1*302  that  was  signiﬁcantly  higher  (p  <  0.05)  than  that
f  the  general  population,  as  shown  in  Table  2.  Likewise,
QA1*0301  was  the  most  prevalent  risk  allele  in  T1D  and  CD
atients.  Nevertheless,  the  higher  frequency  was  only  sig-
iﬁcant  (p  <  0.05)  when  the  T1D  group  was  compared  with
he  newborns  from  the  general  population,  but  not  for  the
D  group.
Based  on  the  frequencies,  a  risk  gradient  was  developed
or  T1D  and  CD  in  the  Sonoran  population,  according  to  the
ifferent  combinations  of  the  4  HLA-DQ2  and  DQ8  alleles
tudied  (Table  3).  Our  ﬁndings  show  that  the  CD  group  was
ore  homogeneous,  resulting  in  fewer  positive  risk  allele
ombinations  than  those  found  in  the  T1D  group.  There-
ore,  the  T1D  patients  presented  with  the  16  possible  allele
ombinations,  whereas  we  found  only  13  in  the  CD  group.
he  remaining  3  combinations  were  grouped  as  ‘‘other’’  for
D  analysis  purposes,  to  complete  the  100%  of  the  control
roup.
For  T1D,  we  obtained  a  risk  gradient  of  1:14-1:126.  Simi-
arly,  for  CD,  the  calculated  gradient  ranged  from  1:6-1:126.
he  3  highest  risks  for  T1D  were  encoded  by  HLA-DQ8  in
ombination  with  DQ2  or  one  of  its  alleles,  or  DQ8  alone.
he  2  highest  risks  for  CD  were  related  to  HLA-DQ8,  as
LA-DQ8/DQB1*0201  or  DQ8  alone,  while  the  third  one  was
LA-DQ2.  The  OR  and  conﬁdence  intervals  for  these  allele
ombinations  are  shown  in  Table  3.
According  to  the  data  obtained,  the  lower  risk  allele
ccounted  for  in  this  population  was  the  DQA1*0501  (OR  0.1,
 = 0.02).
In  relation  to  serologic  screening,  42/44  patients  in  the
iabetes  case  panel  presented  with  positive  anti-gliadin  IgG
ntibodies  and  of  these,  8  were  positive  for  anti-gliadin  IgA
nd  3 of  them  for  anti-tTG  IgA  antibodies,  as  well.  In  the  CD
roup,  16/25  cases  were  positive  for  anti-gliadin  IgA  and  15
ad  anti-tTG  IgA  at  the  time  of  analysis,  indicating  active
D.
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Table  2  Allele  frequencies  of  the  HLA-DQ2  and  HLA-DQ8  haplotypes  in  Sonoran  T1D  and  CD  cases  compared  with  the  general
population (Sonoran  newborns).
Alleles  Sonoran  type  1  diabetes  cases
n =  44
Frequency
Sonoran  celiac  disease  cases
n =  25
Frequency
General  population  (Sonoran
newborns)
n  =  397
Frequency
DQA1*0501  0.272a 0.220a 0.233a
DQB1*0201  0.295b 0.260b 0.132a
DQA1*0301  0.340b 0.300a,b 0.232a
DQB1*0302  0.193b 0.220b 0.105a
n: sample size.
The different superscripts indicate signiﬁcant differences (p < 0.05) between the general population, T1D cases, and CD cases.
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Distinctive  Sonoran  allele  frequency  is  in  all  likelihood  due
to  the  blending  of  native  population  groups  that  were  quite
isolated  from  Mesoamerica  and  the  ﬁrst  Europeans  coming
to  the  Northwest  region  of  Mexico.  The  ﬁrst  immigrants  were
most  probably  people  that  worked  in  the  mines  in  the  east-
ern  mountains  of  the  current  State  of  Sonora  more  than  300
years  ago.  Migrants  were  mainly  Spaniards  from  Andalucía,
Extremadura,  and  the  Basque  regions32,  and  they  admixed
with  the  local  native  groups  of  Mayos,  Yaquis,  Seris,  Pimas,
and  the  Tohono  O’odham  Nation33.  Moreover,  some  addi-
tional  blending  may  have  occurred  through  the  more  recent
immigration  of  people  from  central  and  southern  Mexico,
due  to  agricultural  and  industrial  regional  development.
Thus,  the  State  of  Sonora  has  generated  a  new  population
with  a  complex  genetic  structure  that  has  a  higher  Euro-
pean  and  lower  Amerindian  ancestry  compared  with  other
Mexican  Mestizos20.
The  major  histocompatibility  complex,  or  HLA  in  humans,
is  one  of  the  most  polymorphic  regions  in  the  human
genome34.  Therefore,  haplotype  frequency  presents  a wide
variation  in  different  populations  worldwide.  The  DQ2  fre-
quency  in  Caucasian  populations  from  Western  Europe  has
been  estimated  at  20-30%,  while  HLA-DQ8  frequency  is  com-
mon  in  South  and  Central  America;  approximately  20%  of  the
Amerindians  carry  DQ835.
However,  there  is  a  worldwide  similarity  in  the  frequen-
cies  of  these  alleles  in  patients  with  T1D  and  CD.  For
example,  the  results  presented  for  T1D  match  those  of
Swedish  T1D  patients  (n  =  430)36;  their  frequencies  for  the
DQA1*0501  (0.272)  and  DQB1*0201  (0.281)  alleles  are  statis-
tically  equal  to  those  of  the  Mexicans  in  this  study.  Regarding
the  DQ8-associated  alleles,  Scandinavian  T1D  patients36
carried  signiﬁcantly  higher  frequencies  for  the  DQA1*0301
(0.403)  and  DQB1*0302  (0.364)  alleles  than  the  Sonoran  TD1
children.  Nevertheless,  DQA1*0301  was  the  most  prevalent
allele  in  our  T1D  sample  (0.340).
The  distribution  of  alleles  related  to  the  HLA-DQ2  and
DQ8  haplotypes  has  clinical  relevance.  Both  DQB1*0201  and
*0302  alleles  had  the  greatest  increase  in  prevalence  in  our
T1D  and  CD  sample,  doubling  the  frequency  in  Sonoran  new-
borns.  This  ﬁnding  correlates  with  the  risk  gradient  for  both
A
b
i
liseases,  in  which  the  highest  risk  combinations  include  the
QB1  fractions,  as  previously  described  for  these  diseases  in
ther  populations37.
For  example,  people  of  Iranian  origin  have  the  genotype
QB1*0201/x  or  DQB1*0302/x  in  98%  of  conﬁrmed  CD  cases.
oreover,  in  these  Iranian  cases,  the  DQB1*0201  allele  was
ore  prevalent  in  patients  with  severe  atrophy  and  intesti-
al  mucosal  damage  assessed  by  biopsy,  presenting  a  Marsh
IIa-c  grade38.  In  the  present  study,  four  of  the  CD  cases  had
 Marsh  III  gut  biopsy  result39, and  3  of  them  were  positive
or  the  risk  allele  DQB1*0201.
Meanwhile,  in  T1D,  the  presence  of  DQB1  alleles  has  been
ssociated  with  a  younger  age  at  diagnosis  in  a  European
opulation40 and  the  presence  of  multiple  autoantibodies
n  U.S.  Hispanics41. In  our  Sonoran  sample,  the  presence  of
oth  alleles  was  associated  with  the  development  of  T1D
efore  15  years  of  age  (p  <  0.05).
Although  there  were  no  differences  between  the  T1D
nd  CD  groups  in  the  allele  frequency  analysis,  they  arose
hen  we  assessed  the  risk  gradient.  This  is  because  even
hough  the  proportion  was  similar,  the  way  that  these
lleles  were  distributed  and  combined  varied  from  one
isease  to  another.  Thus,  in  this  population  the  presence
f  the  DQ2  haplotype  alone  accounted  for  a  moderate
1D  risk  (1:91),  whereas  it  represented  a  high  risk  for  CD
1:27).
However,  contrary  to  expectations,  the  HLA-DQ8  was
ore  prevalent  than  the  DQ2  in  the  Sonoran  CD  cases.  This
an  be  attributed  to  the  special  distribution  of  the  risk
lleles  in  the  Sonoran  population,  in  which  DQ8  has  a  similar
revalence  to  that  of  DQ2.  As  a  result,  DQ8  is  more  frequent
n  Sonoran  than  in  European  populations,  so  the  possibility
f  developing  the  disease  increases,  despite  the  fact  that
hysiologically,  DQ8  has  a lower  afﬁnity  than  DQ2  for  binding
mmunogenic  gluten  peptides12.
The  highest  risk  combination  for  T1D  was  HLA-DQ2/DQ8,
hereas  we  could  not  establish  this  association  for  the  CD
roup,  probably  due  to  the  sample  size.  However,  this  com-
ination  also  confers  a  very  high  risk  for  CD  development42. striking  ﬁnding  was  that  the  presence  of  this  rare  com-
ination  of  haplotypes  in  the  Sonoran  general  population
ncreased  the  possibility  of  developing  T1D  to  10%,  regard-
ess  of  other  associated  factors.  Additionally,  according  to
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Table  3  Disease  risk  gradient.  T1D  and  CD  risks  were  evaluated  from  HLA-DQ  allele  frequencies,  considering  a  disease  prevalence  of  1:300  for  T1D  and  1:100  to  1:200  for  CD,
highlighted in  the  table.
T1D  allele  pattern  T1D,  %  (n)  Control,  %  (n)  OR  (CI)  Risk  Risk  OR  (CI)  Control,  %  (n)  CD,  %  (n)  CD  allele  pattern
DQ8,  DQ2  7  (3)  1  (4)  7.18  (1.5-33.2)* 1:14  1:6  17.9  (3.4-93.9)* 0.76  (3)  12  (3)  DQ8,  B1*0201
DQ8, B1*0201  4.65  (2)  0.76  (3)  6.25  (1.0-38.4)* 1:16  1:9  13.6  (4.3-42.1)* 2.26  (9)  24  (6)  DQ8
DQ2, A1*0301  o  DQ2,
B1*0302
27.9  (12)  8.56  (34)  4  (1.8-8.4)* 1:31  1:27  4.69  (1.7-12.8)* 6.41  (25)  24  (6)  DQ2
DQ8 7  (3)  2.26  (9)  3.15  (0.8-12.1)  1:32  1:32  3.26  (0.3-29.0)  1.26  (5)  4  (1)  B1*0201,  B1*0302
A1*0301,  B1*0201  7  (3)  3.02  (12)  2.34  (0.6-8.6)  1:43  1:63  1.61  (0.2-13.1)  2.52  (10)  4  (1)  A1*0501,  A1*0301
o  A1*0501,  B1*0302
B1*0201,  B1*0302  2.32  (1)  1.26  (5)  1.82  (0.2-15.9)  1:54  1:71  1.45  (0.4-5.1)  8.56  (34)  12  (3)  DQ2,  A1*0301  o
DQ2,  B1*0302
A1*0501,  A1*0301  o
A1*0501,  B1*0302
4.65  (2)  2.52  (10)  1.84  (0.3-8.6)  1:54  1:123  0.79  (0.1-3.5)  9.82  (39)  8  (2)  DQ8,  A1*0501
DQ2 7  (3)  6.41  (25)  1.08  (0.3-3.7)  1:91  1:126  0.78  (0.1-6.1)  5.04  (20)  4  (1)  B1*0201
DQ8, A1*0501  9.3  (4)  9.82  (39)  0.91  (0.3-2.7)  1:105  1:294  0.28  (0.06-1.2)  23.56  (94)  8  (2)  A1*0301  o  B1*0302
B1*0201  4.65  (2)  5.04  (20)  0.89  (0.2-3.9)  1:108  No  risk  NA  39.81  (158)  0  Negatives
and  other
combinations
A1*0301  o  B1*0302  18.6  (8)  23.56  (94)  0.71  (0.3-1.5)  1:126
A1*0501  2.32  (1)  17.88  (71)  0.1  (0.01-0.7)* 1:770
Negatives  0  17.88  (71)  NA  No  risk
CI: conﬁdence interval; NA: not available; OR: odds ratio.
* p < 0.05.
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our  results,  that  particular  situation  was  more  common  in
the  T1D  cases  than  in  the  CD  ones.
Concerning  the  T1D  patients,  the  OR  of  the  DQ2/DQ8
genotype  (7.18)  was  higher  than  the  sum  of  the  OR  of  the
DQ2  and  DQ8  haplotypes  (4.23).  This  supports  the  reported
synergic  effects  between  these  haplotypes36.
Nevertheless,  to  have  a  better  estimate  of  the  actual
risk,  it  would  be  necessary  to  consider  situations  in  which
the  person  is  heterozygous  or  homozygous  for  a  given  hap-
lotype,  as  well  as  for  the  HLA-DQ2.2  alleles  that  were
not  analyzed.  The  antigen-presenting  cells  from  individ-
uals  who  are  homozygous  for  the  HLA  susceptibility  alleles
present  gliadin-derived  peptides  more  efﬁciently  than  het-
erozygotes,  correlating  with  disease  risk12.  In  children
from  The  Environmental  Determinants  of  Diabetes  in  the
Young  (TEDDY)  study,  a  cumulative  risk  for  CD  of  11%
was  thus  found  among  homozygous  children  for  the  DR3-
DQ2  haplotype.  This  represents  a  greater  risk  than  the  3%
estimated  risk  among  those  with  the  DR3--DQ2/DR4--DQ8
haplotype43.
Our  results  may  have  interesting  applications  for  identi-
fying  and  estimating  the  risk  for  these  diseases  in  Sonoran
special  groups,  such  as  the  relatives  of  the  patients,  or
those  with  autoimmune  disorders  or  associated  environ-
mental  risk  factors.  In  recent  years,  the  European  Society
for  Pediatric  Gastroenterology,  Hepatology,  and  Nutrition
(ESPGHAN)  working  group  has  recommended  performing
HLA  haplotype  typing  to  add  strength  to  the  diagnosis  of
CD  in  symptomatic  children.  This  approach  is  suggested
for  its  high  negative  predictive  value44 when  small  bowel
biopsies  cannot  be  performed  and  speciﬁc  antibody  titers
are  high.
While  in  more  than  90%  of  the  cases  the  development
of  CD  requires  the  HLA  DQ2  or  DQ8  haplotypes,  some  T1D
cases  also  carried  other  genetic  variants35.  Thus,  as  rec-
ommended  by  the  American  Diabetes  Association,  together
with  the  measurement  of  CD-associated  autoantibodies,
haplotype  analysis  will  be  useful  as  a  screening  tool  in
patients  with  T1D,  even  in  the  absence  of  typical  signs  and
symptoms1.
In  this  study,  we  evaluated  anti-tTG  and  anti-gliadin
antibody  screening  in  children  with  diabetes,  identifying
3  possible  cases  of  CD  in  our  T1D  group,  representing  7%
of  our  diabetic  sample.  These  results  are  below  the  10.7%
previously  reported  in  Mexican  mestizos  with  T1D45,  per-
haps  because  the  T1D  patients  evaluated  were  incidental
cases,  and  the  risk  for  developing  CD  remains  high  through-
out  the  lifetime  of  T1D  patients.  With  the  present  approach,
we  found  that  some  of  the  T1D  cases  had  IgA  anti-gliadins
antibodies.  This  was  probably  due  to  the  fact  that  these
children  went  through  an  acute  process  in  which  intestinal
permeability  was  compromised,  creating  antibodies  against
gliadins,  and  not  necessarily  because  of  CD.  Hence  this
screening  is  a  minimally  invasive  cost-effective  option  for
periodically  monitoring  T1D  patients  and  their  risk  for  devel-
oping  CD.  This  would  opportunely  detect  possible  CD  cases,
avoiding  complications  related  to  late  diagnosis.  In  this  con-
text,  and  especially  in  asymptomatic  patients,  an  endoscopy
and  biopsy  assessment  to  conﬁrm  the  CD  diagnosis  is  recom-
mended.
In  summary,  T1D  and  CD  are  diseases  that  frequently
appear  together.  Since  the  Sonoran  population  has  specialase  in  north-western  Mexico  141
enetic  features  due  to  its  ancestry,  the  T1D  and  CD  haplo-
ype  distribution  was  different  from  that  reported  in  Europe,
ith  a  HLA-DQ2:  HLA-DQ8  ratio  of  1.2:1.  The  allele  com-
ination  that  conferred  the  greatest  risk  for  T1D  in  the
onoran  population  was  the  HLA-DQ8/DQ2  combination,  fol-
owed  by  DQ8  alone  or  combined  with  DQB1*0201,  whereas
he  DQ8/DQB1*0201  combination  had  the  highest  risk  for
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